Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
New findings in cancer vaccines described by F. Botta and co-researchers
June 24th, 2008
According to a study from Locarno, Switzerland, "The aim of the present study was to evaluate the role of beta 2-adrenergic receptors (beta 2-ARs) in the outcome of a dendritic cell (DC)-based cancer vaccine in the murine E.G7-ovalbumin (OVA) model. We found that unlike the beta 2-AR, expressed on antigen loaded DCs, beta 2-ARs expressed in the site of DCs inoculation may influence the efficacy of the antitumor response." "Intradermal injection of Staphylococcus aureus peptidoglycan along with the beta 2-AR-specific antagonist ICI 118,551 increased the local innate cytokine response in tumor-bearing mice. When the adoptive transfer of immature DCs loaded with OVA...
Source: Cancer Weekly (2008-06-24)
|
